【摘要】：目的觀察尼可地爾聯合瑞舒伐他汀對冠狀動脈介入治療患者心肌保護作用。方法將68例擇期進行經皮冠狀動脈介入治療術(PCI)的冠心病患者隨機分為對照組36例和試驗組32例。對照組術前予瑞舒伐他汀10 mg,qd,共3 d;試驗組在對照組的基礎上,術前加用尼可地爾5 mg,tid,共3 d。比較2組患者臨床療效、PCI術前和術后24,48 h血清高敏肌鈣蛋白T(hs-cTnT)、超敏C反應蛋白(hs-CRP)、腫瘤壞死因子-α(TNF-α)、白細胞介素-10(IL-10)水平,以及藥物不良反應的發生情況。結果治療后,試驗組和對照組的顯效率分別為78.13%(25例/32例)和52.78%(19例/36例),差異有統計學意義(P0.05)。PCI術前,試驗組和對照組hs-cTnT水平分別為(36.56±15.35),(30.29±13.67)pg·mL~(-1),hs-CRP分別為(3.67±1.24),(3.53±1.32)mg·L~(-1),TNF-α分別為(6.54±2.42),(6.76±2.15)pg·mL~(-1),IL-10分別為(6.87±1.92),(7.02±1.85)pg·mL~(-1)。PCI術后24 h,試驗組和對照組hs-cTnT水平分別為(71.25±17.87),(82.65±18.34)pg·mL~(-1),hs-CRP分別為(9.48±2.35),(13.56±3.52)mg·L~(-1),TNF-α分別為(8.72±2.26),(10.65±3.16)pg·mL~(-1),IL-10分別為(13.55±4.51),(11.21±3.54)pg·mL~(-1);術后48 h試驗組和對照組hs-cTnT水平分別為(60.56±15.64),(73.54±16.51)pg·mL~(-1),hs-CRP分別為(6.62±1.98),(10.24±2.84)mg·L~(-1),TNF-α分別為(7.56±1.86),(8.86±1.95)pg·mL~(-1),IL-10分別為(11.16±3.28),(9.76±3.11)pg·mL~(-1),術后24 h與術后48 h比較,差異均有統計學意義(均P0.05)。試驗組及對照組均沒有出現明顯的藥物不良反應。結論 PCI術前尼可地爾聯合瑞舒伐他汀可以降低炎性因子,提高IL-10,減輕PCI心肌損傷,安全性好。
[Abstract]:Objective to observe the myocardial protective effect of nicoranil combined with resuvastatin on patients with coronary intervention. Methods Sixty-eight patients with (PCI) undergoing percutaneous coronary intervention were randomly divided into control group (n = 36) and trial group (n = 32). The control group was treated with resuvastatin 10 mg / g QD for 3 days, and the control group was treated with nicorandil 5 mg / d for 3 days. The clinical effects of the two groups were compared. The serum levels of Gao Min troponin T (hs-cTnT), hypersensitive C-reactive protein (hs-CRP), tumor necrosis factor- 偽 (TNF- 偽), interleukin-10 (IL-10) and adverse drug reactions were compared between the two groups. Results after treatment, the effective rates of the experimental group and the control group were 78.13% (25 / 32) and 52.78% (19 / 36), respectively. The difference was statistically significant (P0.05). 璇曢獙緇勫拰瀵圭収緇刪s-cTnT姘村鉤鍒嗗埆涓，

本文編號：2191596